Impact of smoking and its cessation on systemic and airway immune activation08/15/2016 - 06/30/2018 (Subcontract Co-PI)
Boston Medical Center Corporation NIH NIDA5R01DA042685-02
Providence/Boston Center for AIDS Research(CFAR): Core E-Biobehavioral Sciences07/01/2018 - 06/30/2023 (PI)
Miriam Hospital NIH-NIAID
Persistent HIV expression induced type 1 IFN responses and inflammaging08/01/2018 - 04/30/2023 (PI)
Trustees of Boston University NIH-NIAID
Rapid Bacterial Identification (RABIT) Study08/01/2019 - 08/31/2022 (PI)
Day Zero Diagnostics, Inc.
Impact of smoking and its cessation on systemic and airway immune activation08/15/2016 - 06/30/2022 (PI)
NIH-NIDA5R01DA042685-03
PILOT STUDY - EFFECTS OF BICTEGRAVIR-EMTRICITABINE-TENOFOVIR ALAFENAMIDE ON CORONARY FLOW RESERVE…01/01/2019 - 01/31/2022 (PI)
Brigham & Women's
The Effects of Opiod Use on HIV-1 Reservoir Dynamics08/15/2018 - 05/31/2021 (PI)
Brigham & Women's NIH-NIDA1R61DA047038-01
REPRIEVE A5332 Cardiac MRI (substudy): Mechanisms of Cardiac Dysfunction in HIV and the Effect of..06/16/2017 - 03/31/2021 (PI)
Mass General Hosp NIH-NHLBI
MK-0003640000101/10/2018 - 01/09/2021 (PI)
Merck
GS-US-380-4030: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy06/19/2017 - 06/19/2020 (PI)
Gilead Sciences
REPRIEVE A5332 (main study)05/01/2015 - 04/30/2020 (PI)
Mass General Hosp NIH-NHLBI5U01HL123336-05
Showing 10 of 23 results.
Show All Results
REPRIEVE A5332 Supplemental Funding (substudy)05/01/2015 - 04/01/2020 (PI)
Brigham & Women's NIH-NIAID
REPRIEVE A5332 Women's Ancillary Study (substudy)03/01/2017 - 02/28/2020 (PI)
Mass General Hosp NIH-NIAID5R01AI123001-03
Intensified antiretroviral therapy with raltegravir in acute HIV infection to limit establishment…12/10/2014 - 12/31/2019 (PI)
Merck
Phase III, randomized, multi center…switching to dolutegravir plus lamivudine in HIV-111/10/2017 - 11/10/2019 (PI)
GlaxoSmithKline
GS-US-366-1160: a Phase 3b, Randomized, Souble-Blind Study to Evaluate Switching from a Regimen06/17/2015 - 03/31/2019 (PI)
Gilead Sciences
GS-US-380-1878: A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of05/18/2016 - 10/31/2018 (PI)
Gilead Sciences
GS-US-380-1844: A Phase 3, Randomized, Double-Blind Study to Evaluate Switching from a Regimen05/16/2016 - 10/31/2018 (PI)
Gilead Sciences
Lifespan/Tufts/Brown Center for AIDS Research(CFAR): Core E07/01/2017 - 06/30/2018 (PI)
Miriam Hospital NIH-NIAID
Developing a Resilience Intervention for Aging, HIV-Infected Women05/01/2017 - 04/30/2018 (PI)
Mass General Hosp NIH-NCCIH
Ragon Clinical Platform01/01/2015 - 12/31/2017 (PI)
Mass General Hosp
Combining social network, spatial, and phylogenetic approaches to identify new HIV infections02/15/2017 - 07/21/2017 (PI)
Trustees of Boston University NIH-NIAID
AIDS Clinical Trials Group (ACTG)12/01/2016 - 05/08/2017 (PI)
Brigham & Women's NIH-NIAID
Analysis of properties of HIV-1 subtype C envelope glycoprotein06/01/2014 - 04/30/2016 (PI)
NIH-NIAID6K08AI081545-06